ArticleCells2020
Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Machine Learning-Based Prediction of Mononuclear Cell Collection Efficiency for CAR-T Manufacturing.Current medical science · 2026Article
- Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.Transfusion · 2026Article
- Adoptive T-cell therapies in the clinic.Bioengineering & translational medicine · 2026Review
- Biomarker-empowered precision navigation of CAR-T cell therapy.Molecular cancer · 2026Review
- Process Systems Engineering in Precision Medicine: Opportunities in Autologous CAR-T Therapy.Engineering in life sciences · 2026Review
- Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy.Hematological oncology · 2025Article
- Review
- Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy.Cytotherapy · 2025Article
- Immunosenescence, Physical Exercise, and their Implications in Tumor Immunity and Immunotherapy.International journal of biological sciences · 2025Review
- The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.Advanced pharmaceutical bulletin · 2024Review
- Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.Blood transfusion = Trasfusione del sangue · 2024Article
- The effect of physical exercise on anticancer immunity.Nature reviews. Immunology · 2024Review
- Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.Transplantation and cellular therapy · 2024Review
- Universal CAR 2.0 to overcome current limitations in CAR therapy.Frontiers in immunology · 2024Review
- Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel.Blood transfusion = Trasfusione del sangue · 2023Article
- A proposed predictive mathematical model for efficient T-cell collection by leukapheresis for manufacturing chimeric antigen receptor T cells.Haematologica · 2023Article
- Get Off on the Right Foot: How to Plan an Efficient Leukocytapheresis to Collect T Cells for CAR T-Cell Manufacturing.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundT lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication.
methodsA total of 75 unstimulated leukaphereses were analyzed including 45 aphereses in patients and 30 in healthy donors. Thereof, 41 adult patients with Non-Hodgkin's lymphoma (85%) or acute lymphoblastic leukemia (15%) underwent leukapheresis for CAR-T cell production.
resultsSufficient lymphocytes were harvested from all patients even from those with low peripheral lymphocyte counts of 0.18/nL. Only four patients required a second leukapheresis session. Leukapheresis products contained a median of 98 × 10
conclusionsSufficient yield of lymphocytes for CAR-T cell production is feasible also for patients with low peripheral blood counts. Up to 12-15 L blood volume should be processed in patients with absolute lymphocyte counts ≤ 1.0/nL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.